Trial results

Effects of Tirzepatide on Alcohol Intake in Patients Diagnosed With Schizophrenia and Alcohol Use Disorder

NCT06939088 on ClinicalTrials.gov · last registry update 2026-02-10

Recruiting now, toward 108 participants. Due to report 1 August 2028, alongside 21 other tracked readouts that quarter. Primary outcome, as filed: Change in heavy drinking days. Sponsors move these dates routinely; any movement since this site started watching is listed below. tirzepatide is approved in the US, but not for alcohol use disorder and psychiatric — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status

RECRUITING

Phase

P2

Drug

tirzepatide

Zepbound, Mounjaro

Sponsor

Anders Fink-Jensen, MD, DMSci

Sponsor type

Other

Enrollment

108

Started

2025-05-05

Primary completion

2028-08-01 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change in heavy drinking days

Conditions studied

Alcohol Use Disorder · Alcohol Abuse/Dependence · Alcohol Dependence · Alcoholism · Schizophrenia Disorders · Schizophrenia and Disorders With Psychotic Features · Schizophrenia and Schizophrenia Spectrum Psychosis · Schizophrenia

Every field above is taken directly from the registry record. See all detected changes across the class, or the tirzepatide page for this molecule’s full trial and approval history.